AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
GlaxoSmithKline starts human clinical trial of HIV vaccine.(Brief Article)
2002 MAR 6 - (NewsRx.com & NewsRx.net) -- GlaxoSmithKline Biologicals (GSK Biologicals) has started the first trial in humans of its recombinant, adjuvanted candidate HIV vaccine - NefTat and gp 120 formulated with the proprietary adjuvant AS02. The main objectives are to see if the candidate vaccine is safe and whether the human immune system responds to it.
The first human clinical trial of GSK Biologicals' candidate HIV vaccine will be conducted in collaboration with the HIV Vaccine Trials Network (HVTN) in the United States, following the encouraging results from rhesus monkey efficacy studies and other clinical studies on novel adjuvants. The HVTN is sponsored by the National Institute of Allergy and Infectious Diseases, a component of the National Institutes of Health.
"The HVTN welcomes the opportunity to collaborate on this trial with GSK, which brings acknowledged global expertise in vaccine development to the field of HIV vaccine research," said Dr. Larry Corey, principal investigator for HVTN. "The testing of multiple vaccine candidates is critical to speeding progress toward an HIV vaccine and controlling the global pandemic, and we are pleased to offer our clinical trial network to vaccine inventors."
This Phase I safety and immunogenicity trial will start at up to 11 ...
- Start of First Clinical Trial With GlaxoSmithKline Biologicals' Novel HIV...
- Press release article from: PR Newswire January 31, 2002 700+ words
...clinical trial of GSK Biologicals' candidate HIV vaccine will be conducted...earlier trials, GSK Biologicals' candidate HIV vaccine has protected...human studies. "GSK Biologicals is committed to developing an HIV vaccine that will prevent...
- GSK Biologicals aim to triple production by 2010.
- News wire article from: PTI - The Press Trust of India Ltd. April 12, 2006 700+ words
GSK Biologicals aim to triple production by 2010...GlaxoSmithKline Biologicals (GSK Biologicals), an affiliate of the GSK Pharmaceuticals...Limited Chairman D S Parekh said the GSK Biologicals delivered 1.2 billion vaccine...
- Corixa and GSK Biologicals Announce Plans to Initiate a Human Clinical Study in...
- Press release article from: Business Wire January 14, 2004 700+ words
...Biologicals GlaxoSmithKline Biologicals (GSK Biologicals), the world's leading vaccine...research, development and production. GSK Biologicals employs more than 1,000 research...worldwide. Last year, an average of 25 GSK Biologicals vaccine doses per second were delivered...
- Company announces new manufacturing and supply agreement with GSK Biologicals.
- Newspaper article from: Virus Weekly August 24, 2004 700+ words
...the production of Corixa's flagship adjuvant, monophosphoryl lipid A or MPL. Corixa's MPL adjuvant is a component of GSK Biologicals adjuvant systems used in the development of future vaccines currently undergoing clinical trials or awaiting regulatory...
- GSK has also signed a cooperation agreement to form a joint venture, through...
- Magazine article from: Chemistry and Industry Eisberg, Neil December 22, 2008 700+ words
GSK has also signed a cooperation agreement to form a joint venture, through GSK Biologicals, with China's Shenzhen Neptunus Interlong BioTechnique for the co-development of seasonal influenza and pre-pandemic/ pandemic...
- Plexus Vaccine, GSK Biologicals ink research agreement.(Brief Article)
- Newspaper article from: Vaccine Weekly September 25, 2002 700+ words
2002 SEP 25 - (NewsRx.com & NewsRx.net) -- Plexus Vaccine, Inc., has signed a technology development agreement with GlaxoSmithKline Biologicals (GSK Bio) to explore novel approaches for structure-based rational vaccine design. As part of the funded research collaboration, Plexus Vaccine will
- Antigenics extends deal with GSK Biologicals.(Antigenics Licensing agreements...
- Newspaper article from: Pharma Marketletter July 17, 2006 700+ words
New York, USA-based Antigenics says that it has signed expanded license and supply agreements for the use of QS-21 Stimulon adjuvant with GlaxoSmithKline Biologicals, a vaccine division of UK drug major GlaxoSmithKline. QS-21 is a key component included in several of GSK's proprietary adjuvant
- GlaxoSmithKline starts human clinical trial of HIV vaccine.(Brief Article)
- Newspaper article from: AIDS Weekly March 4, 2002 700+ words
...clinical trial of GSK Biologicals' candidate HIV vaccine will be conducted...earlier trials, GSK Biologicals' candidate HIV vaccine has protected...not known. "GSK Biologicals is committed to developing an HIV vaccine that will prevent...
